Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Poor sleep quality is associated with poorer oral health related quality of life in patients with chronic diseases.

Sleep & breathing = Schlaf & Atmung·2026
Same author

A proof-of-concept for a novel mandibular dental implant model in mice.

Clinical oral investigations·2026
Same author

Consensus-based management of endometriosis-associated pelvic pain: Results of a French Delphi study.

Journal of gynecology obstetrics and human reproduction·2026
Same author

Decoding Causality in Periodontal Medicine: Background Factors and Other Sources of Uncertainty.

Journal of periodontal research·2026
Same author

Impact of physical activity on frozen embryo transfer outcomes.

Journal of gynecology obstetrics and human reproduction·2026
Same author

Critical assessment of a prolonged-release EE/DNG contraceptive safety analysis.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2026
Same journal

[Advances and perspectives in vascularized composite allotransplantation preservation].

Bulletin de l'Academie nationale de medecine·2025
Same journal

[COVID-19: Neurological manifestations and complications during the acute phase of the disease].

Bulletin de l'Academie nationale de medecine·2024
Same journal

[Role of psychological factors in post-COVID-19 condition].

Bulletin de l'Academie nationale de medecine·2023
Same journal

[From the origin of Sars-CoV-2 to dangerous virology/biology].

Bulletin de l'Academie nationale de medecine·2023
Same journal

[Neurological forms of long COVID in adults: Critical approach].

Bulletin de l'Academie nationale de medecine·2023
Same journal

[Post-COVID-19 syndrome].

Bulletin de l'Academie nationale de medecine·2023
See all related articles

Related Experiment Video

Updated: Jun 25, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

[Selective progesterone receptor modulators: future clinical applications].

Philippe Bouchard1, Sophie Ouzounian, Nathalie Chabbert-Buffet

  • 1Endocrinologie, Hôpital Saint Antoine, 184 rue du Faubourg Saint Antoine--75012 Paris.

Bulletin De L'Academie Nationale De Medecine
|February 25, 2009
PubMed
Summary
This summary is machine-generated.

Selective progesterone receptor modulators (SPRMs) are valuable in women's health, particularly for their endometrial effects. These agents show promise in treating uterine fibroids, endometriosis, and developing new contraceptive methods.

Related Experiment Videos

Last Updated: Jun 25, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Area of Science:

  • Reproductive endocrinology
  • Pharmacology

Context:

  • Selective progesterone receptor modulators (SPRMs) are a class of drugs with established and emerging applications in women's health.
  • Their primary mechanism of action involves modulating the progesterone receptor, leading to significant effects on the endometrium.

Purpose:

  • To summarize the current and potential applications of SPRMs in gynecology.
  • To highlight their therapeutic value in managing conditions like uterine fibroids and endometriosis.
  • To explore their role in novel contraceptive strategies.

Summary:

  • SPRMs demonstrate efficacy in reducing uterine fibroid volume and associated bleeding, aiding in pre-surgical management.
  • Ongoing research is evaluating SPRMs for the treatment of endometriosis, a common gynecological disorder.
  • SPRMs are being investigated as a potential option for estrogen-free contraception.

Impact:

  • SPRMs offer a promising therapeutic avenue for several gynecological conditions, potentially improving patient outcomes.
  • Their endometrial-specific effects provide targeted treatment options with a favorable side-effect profile.
  • The development of SPRM-based contraception could offer a new, estrogen-free choice for family planning.